PRKDC and neoplasm: Consistent with this, we find that targeting C‐NHEJ with DNA‐PKcs inhibitors enhanced the efficacy of pyridostatin treatment against BRCA1/2‐deficient tumours, thus the two compounds act synergistically in this context.